Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
CASPIAN
A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)
2 other identifiers
interventional
987
23 countries
207
Brief Summary
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2017
Longer than P75 for phase_3
207 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 18, 2017
CompletedFirst Posted
Study publicly available on registry
February 6, 2017
CompletedStudy Start
First participant enrolled
March 27, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 27, 2020
CompletedResults Posted
Study results publicly available
March 4, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedApril 22, 2026
April 1, 2026
2.8 years
January 18, 2017
January 21, 2021
April 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP
OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An interim analysis of OS in the global cohort was pre-specified after approximately 318 OS events occurred each between the D + EP and EP groups (60% maturity), and between the D + T + EP and EP groups (60% maturity). At the global cohort interim analysis DCO (11 March 2019), comparison of OS in the D + EP versus (vs) EP groups had crossed the pre-specified boundary. Since these results were considered final in terms of formal statistical testing, they are presented here as a primary outcome measure. Analysis of OS for D + EP vs EP and for D + T + EP vs EP at the time of the global cohort final analysis is presented separately in the subsequent primary outcome measure.
From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).
OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP
OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. This primary outcome measure presents OS for the analysis of D + EP vs EP and D + T + EP vs EP at the time of the global cohort final analysis DCO (27 January 2020). Analysis of D + EP vs EP at the global cohort interim analysis DCO is presented in the previous primary outcome measure. Analysis of D + T + EP vs D + EP (global cohort final analysis) is presented as a secondary outcome measure.
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP
OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An analysis of OS for D + EP vs EP in the China cohort was pre-specified at approximately 60% maturity (to ensure a similar maturity to the interim analysis of the Global cohort). This primary outcome measure presents OS for analysis of D + EP vs EP at the China cohort first analysis DCO (06 January 2020), and is comparable in terms of maturity with the interim analysis of OS for D + EP vs EP in the Global cohort. Analysis of OS for D + EP vs EP and for D + T + EP vs EP at the time of the China cohort second analysis is presented separately in the subsequent primary outcome measure.
From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).
OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP
OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An analysis of OS for D + T + EP vs EP in the China cohort was pre-specified at approximately 80% maturity (to ensure a similar maturity to the final analysis of the Global cohort). This primary outcome measure presents OS for analysis of D + EP vs EP and D + T + EP vs EP at the time of the China cohort second analysis DCO (02 November 2020), and is comparable in terms of maturity with the final analysis of OS for D + EP vs EP and D + T + EP vs EP in the Global cohort. Analysis of D + EP vs EP at the China cohort first analysis DCO is presented in the previous primary outcome measure. Analysis of D + T + EP vs D + EP (China cohort second analysis) is presented as a secondary outcome measure.
From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Secondary Outcomes (28)
OS in the Global Cohort; D + T + EP Compared With D + EP
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Progression-Free Survival (PFS) in the Global Cohort
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Objective Response Rate (ORR) in the Global Cohort
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Percentage of Patients Alive and Progression Free at 6 Months (APF6) in the Global Cohort
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 6 months post-randomization.
Percentage of Patients Alive and Progression Free at 12 Months (APF12) in the Global Cohort
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 12 months post-randomization.
- +23 more secondary outcomes
Study Arms (3)
Arm 1
EXPERIMENTALdurvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
Arm 2
EXPERIMENTALdurvalumab+EP (carboplatin or cisplatin + etoposide)
Arm 3
ACTIVE COMPARATOREP (carboplatin or cisplatin + etoposide)
Interventions
IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Eligibility Criteria
You may qualify if:
- Histologically or cytologically documented extensive disease. Brain metastases; must be asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.
- Suitable to receive a platinum-based chemotherapy regimen as 1st line treatment.
- Life expectancy ≥12 weeks at Day 1.
- ECOG 0 or 1 at enrolment.
- No prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines.
You may not qualify if:
- Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).
- Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS
- Active infection including tuberculosis, HIV, hepatitis B anc C
- Active or prior documented autoimmune or inflammatory disorders
- Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (207)
Research Site
Birmingham, Alabama, 35235, United States
Research Site
Scottsdale, Arizona, 85259, United States
Research Site
Rogers, Arkansas, 72758, United States
Research Site
Santa Monica, California, 90404, United States
Research Site
New Haven, Connecticut, 06520, United States
Research Site
Athens, Georgia, 30607, United States
Research Site
Fort Wayne, Indiana, 46804, United States
Research Site
Muncie, Indiana, 47303, United States
Research Site
Leawood, Kansas, 66209, United States
Research Site
Wichita, Kansas, 67214, United States
Research Site
Paducah, Kentucky, 42003, United States
Research Site
Grand Rapids, Michigan, 49503, United States
Research Site
Mineola, New York, 11501, United States
Research Site
Cleveland, Ohio, 44106, United States
Research Site
Columbus, Ohio, 43219, United States
Research Site
Harrisburg, Pennsylvania, 17109, United States
Research Site
Sioux Falls, South Dakota, 57104, United States
Research Site
Nashville, Tennessee, 37203, United States
Research Site
Kennewick, Washington, 99336, United States
Research Site
Buenos Aires, C1118AAT, Argentina
Research Site
Ciudad de Buenos Aires, C1426, Argentina
Research Site
Mar del Plata, 7600, Argentina
Research Site
Rosario, 2000, Argentina
Research Site
San Miguel de Tucumán, T4000IAK, Argentina
Research Site
Linz, 4021, Austria
Research Site
Salzburg, 5020, Austria
Research Site
Vienna, 1140, Austria
Research Site
Vienna, 1210, Austria
Research Site
Barretos, 14784-400, Brazil
Research Site
Curitiba, 81520-060, Brazil
Research Site
Passo Fundo, 99010 260, Brazil
Research Site
Porto Alegre, 91350-200, Brazil
Research Site
Ribeirão Preto, 14048-900, Brazil
Research Site
Rio de Janeiro, 22793-080, Brazil
Research Site
Salvador, 41.950-610, Brazil
Research Site
Santo André, 09060-650, Brazil
Research Site
São José do Rio Preto, 15090-000, Brazil
Research Site
São Paulo, 03102-002, Brazil
Research Site
Panagyurishte, 4500, Bulgaria
Research Site
Plovdiv, 4000, Bulgaria
Research Site
Plovdiv, 4004, Bulgaria
Research Site
Sofia, 1330, Bulgaria
Research Site
Sofia, 1431, Bulgaria
Research Site
Sofia, 1618, Bulgaria
Research Site
Sofia, 1784, Bulgaria
Research Site
Varna, 9010, Bulgaria
Research Site
Beijing, 100142, China
Research Site
Beijing, 100730, China
Research Site
Beijing, 100853, China
Research Site
Bengbu, 233004, China
Research Site
Changchun, 130021, China
Research Site
Changsha, 410013, China
Research Site
Chengdu, 610041, China
Research Site
Chongqing, 400038, China
Research Site
Hangzhou, 310003, China
Research Site
Hangzhou, 310006, China
Research Site
Hangzhou, 310009, China
Research Site
Hefei, 230601, China
Research Site
Nanchang, 330006, China
Research Site
Nanjing, 210009, China
Research Site
Nanjing, 210029, China
Research Site
Shanghai, 200032, China
Research Site
Shanghai, 200433, China
Research Site
Shenyang, 110042, China
Research Site
Ürümqi, 830000, China
Research Site
Wenzhou, 325000, China
Research Site
Wuhan, 430022, China
Research Site
Wuhan, 430030, China
Research Site
Xi'an, 710038, China
Research Site
Xi'an, 710061, China
Research Site
Zhanjiang, 524001, China
Research Site
Zhengzhou, 450008, China
Research Site
Zhuhai, 519099, China
Research Site
Brno, 639 00, Czechia
Research Site
Olomouc, 775 21, Czechia
Research Site
Ostrava - Vitkovice, 703 84, Czechia
Research Site
Prague, 128 08, Czechia
Research Site
Prague, 140 59, Czechia
Research Site
Prague, CZ-150 18, Czechia
Research Site
Avignon, 84918, France
Research Site
Brest, 29609, France
Research Site
Créteil, 94010, France
Research Site
La Tronche, 38043, France
Research Site
Pierre-Bénite, 69310, France
Research Site
Rennes, 35033, France
Research Site
Aachen, 52074, Germany
Research Site
Berlin, 13125, Germany
Research Site
Gauting, 82131, Germany
Research Site
Gera, 07548, Germany
Research Site
Hamburg, 20251, Germany
Research Site
Heidelberg, 69126, Germany
Research Site
Mainz, 55131, Germany
Research Site
Regensburg, 93053, Germany
Research Site
Budapest, 1083, Hungary
Research Site
Budapest, 1106, Hungary
Research Site
Budapest, 1121, Hungary
Research Site
Budapest, 1134, Hungary
Research Site
Deszk, 6772, Hungary
Research Site
Gyula, 5700, Hungary
Research Site
Kaposvár, 7400, Hungary
Research Site
Kecskemét, 6000, Hungary
Research Site
Miskolc, 3529, Hungary
Research Site
Pécs, 7624, Hungary
Research Site
Székesfehérvár, 8000, Hungary
Research Site
Jerusalem, 91031, Israel
Research Site
Kfar Saba, 95847, Israel
Research Site
Petah Tikva, 49100, Israel
Research Site
Ramat Gan, 5265601, Israel
Research Site
Bergamo, 24127, Italy
Research Site
Meldola, 47014, Italy
Research Site
Milan, 20133, Italy
Research Site
Palermo, 90146, Italy
Research Site
Roma, 00100, Italy
Research Site
Terni, 05100, Italy
Research Site
Chūōku, 104-0045, Japan
Research Site
Fukuoka, 812-8582, Japan
Research Site
Fukushima, 960-1295, Japan
Research Site
Himeji-shi, 670-8520, Japan
Research Site
Iwakuni-shi, 740-8510, Japan
Research Site
Kashiwa, 227-8577, Japan
Research Site
Kōtoku, 135-8550, Japan
Research Site
Kurume-shi, 830-0011, Japan
Research Site
Kyoto, 606-8507, Japan
Research Site
Matsuyama, 791-0280, Japan
Research Site
Nagoya, 464-8681, Japan
Research Site
Nagoya, 466-8560, Japan
Research Site
Okayama, 700-8558, Japan
Research Site
Sakaishi, 591-8555, Japan
Research Site
Sayama, 589-8511, Japan
Research Site
Tokushima, 770-8503, Japan
Research Site
Ube-shi, 755-0241, Japan
Research Site
Yokohama, 236-0004, Japan
Research Site
Yokohama, 241-8515, Japan
Research Site
Amsterdam, 1066 CX, Netherlands
Research Site
Arnhem, 6815 AD, Netherlands
Research Site
Groningen, 9713 GZ, Netherlands
Research Site
Hengelo, 7555 DL, Netherlands
Research Site
Maastricht, 6202 AZ, Netherlands
Research Site
Rotterdam, 3015 GD, Netherlands
Research Site
Bialystok, 15-027, Poland
Research Site
Bialystok, 15-540, Poland
Research Site
Lublin, 20-954, Poland
Research Site
Olsztyn, 10-357, Poland
Research Site
Warsaw, 02-781, Poland
Research Site
Cluj-Napoca, 400015, Romania
Research Site
Floreşti, 407280, Romania
Research Site
Suceava, 720237, Romania
Research Site
Moscow, 105229, Russia
Research Site
Omsk, 644013, Russia
Research Site
Rostov-on-Don, 344037, Russia
Research Site
Saint Petersburg, 194291, Russia
Research Site
Saint Petersburg, 195271, Russia
Research Site
Saint Petersburg, 196603, Russia
Research Site
Saint Petersburg, 197758, Russia
Research Site
Ufa, 450054, Russia
Research Site
Banská Bystrica, 97517, Slovakia
Research Site
Bardejov, 085 01, Slovakia
Research Site
Bratislava, 82606, Slovakia
Research Site
Bratislava, 833 01, Slovakia
Research Site
Košice, 041 91, Slovakia
Research Site
Nové Zámky, 940 01, Slovakia
Research Site
Trnava, 91708, Slovakia
Research Site
Changwon, 51353, South Korea
Research Site
Cheongju-si, 28644, South Korea
Research Site
Daegu, 42415, South Korea
Research Site
Incheon, 21565, South Korea
Research Site
Jinju, 660-702, South Korea
Research Site
Seongnam-si, 13620, South Korea
Research Site
Seongnam-si, 463-712, South Korea
Research Site
Seoul, 05505, South Korea
Research Site
Seoul, 110746, South Korea
Research Site
A Coruña, 15006, Spain
Research Site
Badajoz, 06008, Spain
Research Site
Badalona, 08916, Spain
Research Site
Barcelona, 08041, Spain
Research Site
Madrid, 08035, Spain
Research Site
Madrid, 28040, Spain
Research Site
Madrid, 28041, Spain
Research Site
Santander, 39008, Spain
Research Site
Valencia, 46010, Spain
Research Site
Zaragoza, 50009, Spain
Research Site
Changhua, 50006, Taiwan
Research Site
Kaohsiung City, 82445, Taiwan
Research Site
Kaohsiung City, 83301, Taiwan
Research Site
Taichung, 40447, Taiwan
Research Site
Taichung, 40705, Taiwan
Research Site
Tainan, 704, Taiwan
Research Site
Tainan, 736, Taiwan
Research Site
Taipei, 11217, Taiwan
Research Site
Taipei, 235, Taiwan
Research Site
Ankara, 06230, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Edirne, 22030, Turkey (Türkiye)
Research Site
Istanbul, 32098, Turkey (Türkiye)
Research Site
Izmir, 35100, Turkey (Türkiye)
Research Site
Izmir, 35620, Turkey (Türkiye)
Research Site
Dnipro, 49102, Ukraine
Research Site
Ivano-Frankivsk, 76018, Ukraine
Research Site
Kirovohrad, 25006, Ukraine
Research Site
Kryvyi Rih, 50048, Ukraine
Research Site
Kyiv, 03022, Ukraine
Research Site
Kyiv, 03115, Ukraine
Research Site
Lviv, 79031, Ukraine
Research Site
Odesa, 65055, Ukraine
Research Site
Sumy, 40022, Ukraine
Research Site
Vinnytsia, 21029, Ukraine
Research Site
Zaporizhzhia, 69040, Ukraine
Related Publications (4)
Ozguroglu M, Goldman JW, Chen Y, Garassino MC, Medic N, Mann H, Chugh P, Dalvi T, Paz-Ares L. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May;21(12):1511-1523. doi: 10.1080/14796694.2025.2491297. Epub 2025 May 7.
PMID: 40331625DERIVEDXie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, Byers LA, Rudin CM, Shrestha Y. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30;23(1):115. doi: 10.1186/s12943-024-02014-x.
PMID: 38811992DERIVEDGoldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.
PMID: 33285097DERIVEDPaz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
PMID: 31590988DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Analysis of the China cohort was performed to evaluate the consistency of efficacy and safety in Chinese patients with the global cohort in order to meet regulatory requirements and was not powered for a formal assessment of statistical significance.
Results Point of Contact
- Title
- Global Clinical Lead
- Organization
- AstraZeneca
Study Officials
- STUDY DIRECTOR
Haiyi Jiang, M.D.
AstraZeneca
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 18, 2017
First Posted
February 6, 2017
Study Start
March 27, 2017
Primary Completion
January 27, 2020
Study Completion (Estimated)
December 31, 2026
Last Updated
April 22, 2026
Results First Posted
March 4, 2021
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.